Zobrazeno 1 - 10
of 365
pro vyhledávání: ''
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:533-542
Genetic variation in the activation of the prodrug cyclophosphamide (CP) by cytochrome P450 (CYP) enzymes has been shown to influence outcomes. However, CYP are also subject to phenoconversion due to either the effects of comedications or cancer asso
Autor:
Motohiro Fujiwara, Yoshinobu Komai, Shinya Yamamoto, Ryo Fujiwara, Tomohiko Oguchi, Noboru Numao, Shotaro Yasuoka, Junji Yonese, Takeshi Yuasa
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:525-531
In this study, we investigated the association between the early response of serum and hematological variables and the outcome of cabazitaxel therapy. The medical records of 59 consecutive patients who had previously received docetaxel chemotherapy f
Autor:
Masaji Tani, Shin-ya Morita, Tomohiro Terada, Naoki Yabuta, Daiki Hira, Hiroya Iida, Masatomo Sudou, Satoshi Noda, Akira Andoh, Yoshinori Wakasugi, Takehide Fujimoto
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:281-288
Purpose:We aimed to evaluate exposure-toxicity/efficacy relationship of lenvatinib by determining its target trough concentration for patients with hepatocellular carcinoma (HCC).
Methods:In this retrospective, observational study, 28 HCC patien
Methods:In this retrospective, observational study, 28 HCC patien
Autor:
Benjamin Wu, Mathilde Marchand, Nitzan Sternheim, Rene Bruno, Valerie Quarmby, Marcus Ballinger, Rong Zhang, Jin Y. Jin, Phyllis Chan
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:211-221
The time-varying clearance (CL) of the PD-L1 inhibitor atezolizumab was assessed on a population of 1519 cancer patients (primarily with non-small-cell lung cancer or metastatic urothelial carcinoma) from three clinical studies. The first step was to
Autor:
Yuhki Sakuraoka, Shozo Mori, Takayuki Shiraki, Yukihiro Iso, Takatsugu Matsumoto, Keiichi Kubota, Takamune Yamaguchi, Takayuki Shimizu, Kyung Hwa Park, Taku Aoki
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:109-120
Recently, the number of patients with pancreatic ductal adenocarcinoma (PDAC) who have received both neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) has been increasing. However, whether adverse events (AEs) during AC influence the prog
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:69-79
Characterize the population PK and exposure–response (ER) relationships of selinexor in patients with diffuse large B-cell lymphoma (DLBCL) (efficacy endpoints) or other non-Hodgkin’s lymphoma (NHL) patients (safety endpoints) to determine the op
Autor:
Keiichiro Ishibashi, Masahito Kotaka, Toru Aoyama, Yasushi Tsuji, Naoki Nagata, Hironaga Satake, Junichi Sakamoto, Masato Nakamura, Koji Oba, Masato Kataoka, Hideyuki Mishima
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background The aim of this study was to evaluate the efficacy and safety of first-line chemotherapy with re-introduction of oxaliplatin (OX) more than 6 months after adjuvant chemotherapy including OX. Methods Stage II/III colon cancer patients with
Autor:
Kaito Shibata, Junichi Kawakami, Satoshi Hirakawa, Hiroyuki Mineta, Seiji Hosokawa, Koji Suzuki, Takafumi Naito
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87(4):555-565
Purpose: Cetuximab inhibits epidermal growth factor receptor (EGFR) signaling in cancer and skin cells, thereby inducing anti-cancer effects and skin disorders. The present study aimed to evaluate the relationships between serum cetuximab and EGFR-re
Autor:
Hélène Behal, Anthony Turpin, Simon Baldacci, Enora Vauléon, Renaud Desbarbieux, Nicolas Simon, Marie-Hélène Vieillard, Diane Pannier, Loïc Lebellec
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:533-541
The occurrence of arthralgia and myalgia during treatment with bevacizumab (Bev) has been described but not spontaneously reported. We aimed to evaluate the frequency of arthralgia in patients treated with Bev and identify the risk factors. In this o
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:405-414
To investigate the effects of FSTL1-mediated NF-κB signaling pathway on cisplatin (DDP) sensitivity of EOC cells. FSTL1 expression was determined in epithelial ovarian cancer (EOC) tissues and corresponding adjacent tissues using immunohistochemistr